Atrium Therapeutics RNA Stock
Atrium Therapeutics Price Chart
Atrium Therapeutics RNA Financial and Trading Overview
| Atrium Therapeutics stock price | 14 USD |
| Previous Close | 13.48 USD |
| Open | 13.53 USD |
| Bid | 13.24 USD x 100 |
| Ask | 13.29 USD x 100 |
| Day's Range | 12.96 - 13.53 USD |
| 52 Week Range | 11.13 - 16.77 USD |
| Volume | 179.5K USD |
| Avg. Volume | 191.88K USD |
| Market Cap | 225.79M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.44 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25 USD |
RNA Valuation Measures
| Enterprise Value | -36422512 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.637717 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 6.300597 |
| Price/Book (mrq) | 0.9644893 |
| Enterprise Value/Revenue | -1.016 |
| Enterprise Value/EBITDA | 0.531 |
Trading Information
Atrium Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -10.50% |
| S&P500 52-Week Change | 18.67% |
| 52 Week High | 16.77 USD |
| 52 Week Low | 11.13 USD |
| 50-Day Moving Average | 12.47 USD |
| 200-Day Moving Average | 13.03 USD |
RNA Share Statistics
| Avg. Volume (3 month) | 191.88K USD |
| Avg. Daily Volume (10-Days) | 166.09K USD |
| Shares Outstanding | 17.11M |
| Float | 15.09M |
| Short Ratio | 20.92 |
| % Held by Insiders | 4.26% |
| % Held by Institutions | 84.87% |
| Shares Short | 3.59M |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 20.53% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -184.14% |
| Operating Margin (ttm) | -752.92% |
| Gross Margin | -56.36% |
| EBITDA Margin | -191.22% |
Management Effectiveness
| Return on Assets (ttm) | N/A |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 35.84M USD |
| Revenue Per Share (ttm) | 2.1 USD |
| Quarterly Revenue Growth (yoy) | -21.89% |
| Gross Profit (ttm) | -20200000 USD |
| EBITDA | -68528000 USD |
| Net Income Avi to Common (ttm) | -65992000 USD |
| Diluted EPS (ttm) | -5.35 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 263.9M USD |
| Total Cash Per Share (mrq) | 15.43 USD |
| Total Debt (mrq) | 1.68M USD |
| Total Debt/Equity (mrq) | 0.78 USD |
| Current Ratio (mrq) | 8.73 |
| Book Value Per Share (mrq) | 13.686 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -53188000 USD |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Atrium Therapeutics
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 10578 Science Center Drive |
| ZIP | 92121 |
| Phone | 619 876 0700 |
| Website | https://atriumtherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Q&A For Atrium Therapeutics Stock
What is a current RNA stock price?
Atrium Therapeutics RNA stock price today per share is 14 USD.
How to purchase Atrium Therapeutics stock?
You can buy RNA shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Atrium Therapeutics?
The stock symbol or ticker of Atrium Therapeutics is RNA.
Which industry does the Atrium Therapeutics company belong to?
The Atrium Therapeutics industry is Biotechnology.
How many shares does Atrium Therapeutics have in circulation?
The max supply of Atrium Therapeutics shares is 17.11M.
What is Atrium Therapeutics Price to Earnings Ratio (PE Ratio)?
Atrium Therapeutics PE Ratio is now.
What was Atrium Therapeutics earnings per share over the trailing 12 months (TTM)?
Atrium Therapeutics EPS is -5.44 USD over the trailing 12 months.
Which sector does the Atrium Therapeutics company belong to?
The Atrium Therapeutics sector is Healthcare.
Atrium Therapeutics RNA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26151.3 USD — |
+0.66
|
6.58B USD — | 26034.35 USD — | 26225.83 USD — | — - | 6.58B USD — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
|
US Tech Global Market Composite
NQGM
US
|
2327.37 USD — |
+1.32
|
— — | 2318.62 USD — | 2334.08 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7380.34 USD — |
+1.82
|
— — | 7289.6 USD — | 7402.96 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1378.65 USD — |
+1.27
|
— — | 1366.6 USD — | 1381.83 USD — | — - | — — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
3196.25 USD — |
+0.33
|
— — | 3190.59 USD — | 3204.24 USD — | — - | — — |
- {{ link.label }} {{link}}
